MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

October 31, 2024 01:51 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

SHENZHEN, China, Oct. 31, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Special Mention in the TIME Best Inventions 2024 list.

TIME Best Inventions 2024
TIME Best Inventions 2024

TIME Best Inventions recognizes products, software, or services that are revolutionizing the world. Curated by a network of TIME editors, the annual list recognizes inventions big and small from around the globe. This year, the DNBSEQ-T20x2 joined the ranks of the world's most groundbreaking products, technologies, and services for its creativity, meaningful innovation, and significant impact on modern healthcare.

MGI's DNBSEQ-T20x2 ultra-high-throughput sequencer has garnered prominent interest and attention since its debut in February 2023 for bringing down the cost of genome sequencing to 50,000 WGS per year for under $100 per 30x human genome. It was specifically recognized for its leading-edge applications in biotech and for laying the groundwork for more accessible and cost-effective high-throughput sequencing.

By providing scalable genome sequencing capabilities, the DNBSEQ-T20x2 enables researchers to perform large-scale genomic analyses at a reduced cost, thereby opening more doors to delivering research on precision medicine. These capabilities are especially impactful in areas where accurate and affordable sequencing can be leveraged to improve outcomes, such as oncology, rare disease research, and public health initiatives.

Since its launch, the DNBSEQ-T20x2 has earned accolades worldwide, including the Edison Award, iF Design Award, R&D 100 Award, BEYOND Healthcare Innovation Award, Biotech Breakthrough Award, and Globee Award. Each of these recognitions demonstrates the DNBSEQ-T20x2's design excellence, technical performance, and transformative potential in the field of life sciences and healthcare.

"Being featured as a Special Mention in TIME Best Inventions 2024 is a tremendous honor for MGI. It not only celebrates the fruits of our labor; it reinforces our commitment to pushing the boundaries of innovation in genomic technology," said Duncan Yu, President at MGI. "The DNBSEQ-T20x2 is setting a new standard for sequencing efficiency and accessibility, helping make genomics a foundational tool in healthcare for people around the world."

In addition to marking an important milestone for MGI, the DNBSEQ-T20x2's recognition by TIME highlights the broader role of genomics in the future of healthcare. By providing researchers, clinicians, and healthcare professionals with affordable, high-throughput sequencing capabilities, MGI is empowering breakthroughs and advancing precision medicine, early diagnostics, and preventive care for all.

* The DNBSEQ-T20x2 Genetic Sequencer is for research use only and could not be used for any diagnostic procedures.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.